Loading...
Loading...
Bristol-Myers
Squibb Company
BMY today announced that it has
entered into two individual agreements with ViiV Healthcare, a global
HIV company, to divest its pipeline of investigational HIV medicines
consisting of a number of programs at different stages of discovery,
preclinical and clinical development. Under these agreements, ViiV will
pay to Bristol-Myers Squibb upfront payments totaling $350 million with
potential development and regulatory milestone payments of up to $518
million for the clinical assets and up to $587 million for the discovery
and pre-clinical programs. Once products are approved and
commercialized, ViiV Healthcare will pay tiered royalties. Additionally,
ViiV Healthcare will pay sales-based milestone payments of up to $750
million for each of the clinical assets
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in